Cagrilintide 10 mg

Peptide Hubs Cagrilintide

Cagrilintide represents the cutting edge of metabolic research peptides, offered as a 10 mg lyophilized powder. This long-acting dual amylin and calcitonin gene-related peptide (CGRP) receptor agonist has demonstrated profound effects on appetite regulation and weight management in clinical studies. With a third-party lab test confirming an exceptional 12.27 mg per vial—exceeding the labeled 10 mg—researchers receive a premium, accurately dosed compound. For bodybuilders, athletes, and fitness researchers focused on body recomposition, Cagrilintide offers a sophisticated mechanism for investigating sustained appetite suppression and fat loss without the stimulant side effects of traditional weight-loss compounds.

Cagrilintide Composition

Each sterile 2 mL vial contains 10 mg of Cagrilintide, a synthetic 37-amino acid peptide analog of the pancreatic hormone amylin. The molecule is engineered with fatty acid side chains to dramatically extend its half-life, enabling once-weekly administration in research models. The product is presented as a pure, white lyophilized powder without additives, requiring reconstitution with bacteriostatic water before use in a research setting. This formulation ensures maximum stability and potency for investigative protocols.

Bodybuilding and Athletic Research Benefits

In research models, Cagrilintide demonstrates transformative potential for body composition studies. Its primary investigational benefits include profound, sustained appetite reduction leading to significant calorie deficit without conscious effort—valuable for contest prep or cutting phases. Unlike stimulants, it works centrally in the brain's appetite centers. Research suggests it may also increase energy expenditure and promote preferential fat loss while preserving lean muscle mass during calorie restriction. For athletes, this makes it a subject of high interest for achieving ultra-lean physiques with minimal muscle catabolism and without the metabolic slowdown typically associated with dieting.

Therapeutic and Research Indication

While a research chemical, Cagrilintide has been extensively studied in clinical trials for obesity management. As a long-acting amylin analog, it mimics the action of endogenous amylin, which is co-secreted with insulin and promotes satiety, slows gastric emptying, and modulates glucose metabolism. According to research published in The Lancet Diabetes & Endocrinology, Cagrilintide demonstrated significant dose-dependent weight reduction in phase 2 trials. Furthermore, studies referenced by the National Institutes of Health (NIH) highlight its novel mechanism as a dual agonist with promising metabolic effects, distinguishing it from single-mechanism GLP-1 drugs.

Mechanism of Action: Dual Pathway Appetite Control

Cagrilintide operates through two primary pathways. First, as an amylin receptor agonist, it activates receptors in the area postrema of the brainstem, a region lacking a blood-brain barrier, signaling satiety and reducing food intake. Second, it acts as a CGRP receptor antagonist, which may further modulate appetite and energy balance. This dual action results in reduced hunger, increased feelings of fullness after meals, and delayed gastric emptying, leading to sustained calorie reduction. Its once-weekly activity profile is due to albumin binding via its fatty acid chain.

Dosage for Research (Men)

Research protocols for Cagrilintide are based on clinical trial data. In human obesity studies, effective doses ranged from 1.2 mg to 4.5 mg administered once weekly via subcutaneous injection. For athletic and bodybuilding research into body recomposition, investigative doses often start at the lower end of this spectrum (e.g., 1.2-2.4 mg weekly) to assess tolerance and effect. Given its long half-life (~7-8 days), once-weekly administration is sufficient. Research cycles typically span 12-24 weeks to align with meaningful body composition changes.

Dosage for Research (Women)

Research dosing for female subjects generally follows the same milligram-per-week protocols as for men, often initiating at 1.2 mg weekly. Clinical trials have shown similar efficacy and safety profiles across genders. However, as with all metabolic research, individual variation in response should be accounted for in study design. Conservative dose titration (e.g., starting low and increasing gradually) is a prudent research approach.

Active Life and Half-Life

Cagrilintide has an exceptionally long half-life of approximately 7-8 days in humans, attributable to its albumin-binding design. This allows for once-weekly dosing while maintaining stable plasma concentrations. The pharmacological effects on appetite and gastric emptying persist throughout the dosing interval, providing continuous research effect without daily administration peaks and troughs.

Cagrilintide Side Effects

In clinical research, the most commonly reported effects are gastrointestinal and dose-dependent. These include transient nausea, vomiting, diarrhea, and constipation, especially during dose escalation. These effects typically diminish over several weeks as tolerance develops. Unlike stimulant-based appetite suppressants, Cagrilintide is not associated with increased heart rate, blood pressure, or central nervous system stimulation. Hypoglycemia is rare when used in non-diabetic research models.

Contraindications and Precautionary Measures

Cagrilintide is contraindicated in research involving subjects with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), due to theoretical CGRP receptor activity. It should not be used in subjects with severe gastrointestinal disease. Caution is advised in research designs involving subjects with pancreatitis or gallstone history. It is for research use only in laboratory settings.

Overdosage in Research

Overdosage would likely exacerbate gastrointestinal side effects, leading to severe nausea, vomiting, and potential dehydration. There is no specific antidote; management in a research context would involve supportive care and cessation of the compound. The wide therapeutic window observed in clinical trials suggests a good safety margin, but adherence to established research dosing is critical.

Cagrilintide Stack/Cycle for Research

Cagrilintide can be researched in combination with other peptides that have complementary or synergistic mechanisms for body recomposition. Potential research stacks include:

• Tesamorelin to investigate combined effects on visceral fat reduction (Tesamorelin) and overall appetite/weight control (Cagrilintide).
• Ipamorelin to study the preservation of lean muscle mass and growth hormone pulse during the calorie deficit induced by Cagrilintide.
• Survodutide for research comparing dual GLP-1/glucagon receptor agonism with dual amylin/CGRP activity.

These stacks are conceptual frameworks for sophisticated metabolic research only.

Package Presentation

The product is supplied as one sterile glass vial containing 10 mg of Cagrilintide as a white lyophilized powder. The vial is sealed with a rubber stopper and aluminum crimp to ensure sterility. It is shipped in discreet, temperature-conscious packaging to maintain stability.

Storage

For long-term stability of the lyophilized powder, store at or below -20°C (-4°F). For short-term use (under 30 days), refrigeration at 2-8°C (36-46°F) is acceptable. After reconstitution, the solution should be refrigerated and used within the timeframe specified by sterile research guidelines. Due to the peptide's long-acting nature, single-use reconstitution for weekly dosing is a common research practice.

Cagrilintide Referrers

The development and clinical profile of Cagrilintide are well-documented in peer-reviewed literature. Key references include phase 1 and 2 trial results published in major endocrinology journals, detailing its pharmacokinetics, efficacy, and safety. Researchers should consult these primary sources, including clinical trial registries and NIH resources, to design rigorous, evidence-based studies.

Third-Party Lab Test

2026-01-12

View Result

12.27 mg